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The extracellular matrix crosslinking enzyme transglutaminase 2 (TG2) is highly implicated in 
tissue fibrosis that precedes end-stage kidney failure. TG2 is unconventionally secreted 
through extracellular vesicles in a way that depends on heparan sulphate (HS) proteoglycan 
syndecan-4 (Sdc4), the deletion of which reduces experimental kidney fibrosis as a result of 
lower extracellular TG2 in the tubule-interstitium. Here we establish a model of TG2 
externalisation in NRK-52E tubular epithelial cells subjected to glucose stress.  HS-binding 
TG2 mutants had reduced extracellular TG2 in transfected NRK-52E, suggesting that TG2-
externalisation depends on an intact TG2 heparin binding site. Inhibition of N-ethylmaleimide 
sensitive factor (NSF) vesicle-fusing ATPase, which was identified in the recently elucidated 
TG2 kidney membrane-interactome, led to significantly lower TG2-externalisation, thus 
validating the involvement of membrane fusion in TG2 secretion. As cyclin-G-associated 
kinase (GAK) had emerged as a further TG2-partner in the fibrotic kidney, we investigated 
whether glucose-induced TG2-externalisation was accompanied by TG2 phosphorylation 
in consensus sequences of cyclin-dependent kinase (CDK). Glucose stress led to intense TG2 
phosphorylation in serine/threonine CDK-target. TG2 phosphorylation by tyrosine kinases was 
also increased by glucose. Although the precise role of glucose-induced TG2 phosphorylation 
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Transglutaminase 2 (TG2) is a member of a family of Ca2+-dependent transamidases. It 
catalyses the reaction between a glutamyl residue and a lysine residue of the same or different 
proteins forming a stable and proteolytic resistant ε-(γ-glutamyl)-lysine isodipeptide crosslink.  
GTP can block the enzyme activity by stabilizing the enzyme in its closed conformation and 
inhibiting Ca2+ binding to the enzyme [1], furthermore an oxidising environment limits the 
accessibility of the Cys active site for transamidation [2-4]. In reducing conditions, Ca2+ 
binding lowers the enzyme affinity for GTP/GDP, leading to an enzymatically active “open” 
conformation (recently reviewed in [5]). Therefore, TG2 is regarded to be predominantly 
inactive intracellularly in physiologically “normal” conditions and active outside the cells, 
where it targets several extracellular matrix (ECM) proteins leading to ECM remodelling and 
contributing to the scarring process. TG2 has been implicated in a number of fibrotic diseases 
such as tissue fibrosis in liver [6, 7], lung [8, 9], heart [10, 11], kidney [12-15], and in 
atherosclerosis [16, 17]. Its pathological role in the kidney has been extensively studied 
[reviewed in [13]]. In tubular epithelial cells, increased extracellular release of TG2 causes 
extensive ECM accumulation by accelerating collagen deposition as well as by stabilising the 
ECM against the action of matrix metalloproteinases [18]. Furthermore, it acts as a rate-
determining factor in latent transforming growth factor-β (TGF-β) activation by crosslinking 
the large latent TGF-β into the ECM, thus priming it for activation, as observed in OK and 
NRK-52E proximal-like tubular epithelial cells (TEC) [19, 20]. Extracellular TG2 and TG2 
activity are increased in experimental models of chronic kidney disease (CKD) [14, 20, 21] 
and TG2 deletion results into lower levels of active TGF-β [22, 23]. Both extracellular TG2 
and its crosslinking products are also reported to positively correlate with scores of fibrosis 
evaluated in human kidneys with different types of CKD [24], and modulation of TG2 activity 
results in decreased kidney scarring and kidney function preservation in both diabetic [25] and 
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non-diabetic [26] models of experimental CKD. Targeting TG2 externalisation is therefore an 
important strategy to control the scarring process. 
Unlike most exported proteins, TG2 does not possess a signal peptide, and how TG2 is 
externalised into the extracellular environment has been object of intense scrutiny. Recently, 
the presence of clusters of exosomal proteins in the TG2-membrane interactome has led to the 
demonstration that TG2 can be externalised via extracellular membrane vesicles by TEC during 
CKD progression, in a way which is dependent on the heparan sulphate (HS) proteoglycan 
syndecan-4 [22]. TG2 affinity for the HS chains has led to the mapping of the TG2 heparin 
binding site, showing that heparin binding is lost when TG2 is in the linear (“active”) 
conformation [27-29] [recently reviewed in [30]]. Vesicular secretion of TG2 has been 
proposed also in other cell systems [31], and the N-ethylmaleimide (NEM), inhibitor of 
membrane fusion of NSF ATPase, has been shown to interfere with TG2 secretion in NIH/3T3 
[31]. Moreover, TG2 has been shown to be present in cancer shed microvesicles [32], 
externalised from smooth muscle cells in via microvesicles in a transamidation dependent way 
[33], and in stressful conditions such as those seen in abnormal proteostasis. Unconventional 
secretion mechanisms can be distinguished in vesicular and non-vesicular mechanisms [34], 
the latter characterised by direct translocation through the plasma membrane. A well described 
example is that of FGF2 secretion which involves binding to HS proteoglycans [35, 36], in 
common with TG2 externalisation, and also plasma membrane phosphoinositides (PIPs). 
According to this model, FGF2 binds PIPs on the inner side of the plasma membrane leading 
to oligomerisation and formation of a hydrophilic pore. HS chains of the HSPG on the outer 
side would trap FGF2 facilitating its secretion [37], which would require the folded 
conformation and FGF2 phosphorylation by a Tec non-receptor tyrosine kinase [38]. In 
addition, ATP1A1, an α1-chain of sodium/potassium-ATPase has been shown to be a crucial 
factor for the export of FGF2 [39]. Although our in vivo proteomic approach combined with in 
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vitro investigations have identified a HS-dependent vesicular transport for TG2, we do not 
know if this is the unique pathway, and investigations of phosphorylation events in connection 
with TG2 secretion have never been carried out. Moreover, we do not know if an intact TG2 
heparin binding site is required. Here we give mechanistic insights on the externalisation of 
TG2 in NRK-52E TEC induced by glucose exposure. We show that glucose-stimulated release 
of TG2 requires an intact HS binding site and membrane fusion events. Furthermore, we show 






2.  Experimental Material and Methods 
 
2.1 Cell lines 
NRK-52E proximal-like tubular epithelial cells (TEC) were obtained from the European Cell 
Culture Collection and were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Sigma, UK) supplemented with 5% heat-inactivated foetal calf serum (FCS) (Biosera, UK), 2 
mM L-glutamine (Lonza, UK), 100 IU/mL penicillin and 100 μg/mL streptomycin (Sigma, 
UK).  All cultures were maintained at 37°C and in a humidified atmosphere of 5% CO2. EGFP-
TG2 NRK-52E stably transfected clone  [22] was cultured in medium supplemented with G418 
(400 µg/ml). 
 
2.2 Construction of pEGFP-N1-TG2(M1c) and pEGFP-N1-TG2(M3) plasmids  
TGM2 cDNA TG2(M1c) and TG2(M3) cDNA (produced by site directed mutagenesis [27], 
were amplified by PCR using Pwo-DNA polymerase (Roche) and the EcoRI-modified primers 
5’-ATCAGAATTCATGGCCGAGGAGCTGGTCTTAGAGAGG-3’ and 
5’-ATCAGAATTCCGGCGGGGCCAATGATGACATTCCGG-3’, and then subcloned into 
the EcoRI-site of pEGFP-N1 plasmid (BD Biosciences). The obtained pEGFP-N1-TG2 
plasmid expresses TG2 fused in frame to the N-terminus of EGFP.  
 
2.3 Transient transfection of NRK-52E cells 
Transient transfection of NRK-52E TEC with plasmid expressing wild type (WT) or mutated 
TGM2 cDNA were performed using 5μg of either pEGFP-N1-TG2 [22], pEGFP-N1-
TG2(M1c) or pEGFP-N1-TG2(M3). Transfections were carried out by electroporation on an 






2.4 Glucose induction and cell treatments 
For glucose stress simulation, NRK-52E cells were grown in DMEM containing 6 mM D-
Glucose for 7 days. After this time, cells were cultured in the same medium supplemented with 
increasing concentration of D-Glucose (6, 12, 18, 24 and 30 mM) for up to 96 hours [40]. In 
order to cleave heparan sulphate chains or block HS binding, cells cultured in 24 mM D-
Glucose were incubated with either 30 mU/ml Heparinase I (Sigma, UK) or 12 mol/L Surfen 
[bis-2-methyl-4-amino-quinolyl-6-carbamide, a gift from J.D. Esko (University of California, 
San Diego)], at 37oC for an hour. 
For N-ethylmaleimide (NEM) treatment, cells were cultured in 24 mM glucose containing 
medium as until 90% confluent. At this point, medium was supplemented with 0.6 mM NEM 
(E3876, Sigma; from a 12.5 mg/ml freshly prepared in aqueous solution) and cells were 
incubated for 30 min at 37°C as previously described [31].  
 
2.5 Knock Down of Sdc4 expression in NRK-52E cells and clones by siRNA 
transfection 
In order to knock down the expression of Sdc4 in NRK-52E cells or EGFP-TG2 expressing 
clones, transient transfection using Sdc4-targeting siRNA was performed. 3x105 cells per well 
were plated in a 6-well plate in 5% FCS supplemented medium without antibiotics, containing 
24 mM D-Glucose. The day after cells were transfected with either 100 nM Rat Sdc4-targeting 
siRNA or non-targeting scrambled control siRNA, using DharmaFECT-1 solution 
(Dharmacon, UK) as transfection reagent and antibiotic-free complete medium. Cells were 
allowed to grow 24 hrs after transfection. Furthermore, the efficiency of knock down was 
assessed by quantitative RT-PCR (qRT-PCR) using specific primers against rat Sdc4 (5’-
GAGTCGATTCGAGAGACTGA-3’ and 5’-AAAAATGTTGCTGCCCTG-3’). Cyclophilin 
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A was amplified from the same cDNA using appropriate primers (5’-
ACGCCGCTGTCTCTTTTC-3’ and 5’-CTTGCCACCAGTGCCATTAT-3’), and was used as 
an housekeeping gene. After amplification, threshold cycle (Ct) values were obtained and 
averaged among replica. The 2-ΔΔCt relative quantification method [41] was employed to 
calculate the level of expression of the target gene.  
 
2.6 Immunoprecipitation 
Cell lysates were produced in 500 μl of IP Lysis/Wash buffer (Thermo Scientific, UK). For the 
detection of phosphorylation 1% (v/v) protease inhibitors cocktail (P8340 Sigma), 1% (v/v) 
phosphatase inhibitors [phosphatase inhibitor cocktail 2 (P5726 Sigma, UK) and phosphatase 
inhibitor cocktail 3 (P0044 Sigma, UK)] were added to the lysate to inhibit dephosphorylation. 
EGFP-immunoprecipitation was performed in equal amounts of proteins (750 μg) with 2.5 μg 
of rabbit polyclonal anti-GFP antibody (Ab290, Abcam, UK), using the Pierce™ Crosslink 
Magnetic IP/Co-IP Kit (Thermo Scientific, UK), following the manufacturer’s instruction. As 
a negative control, the same procedure was performed in the absence of antibody (referred to 
as “beads only” control).  
 
2.7 Western Blotting  
Equal amount of proteins were separated by SDS-PAGE on a 10% (w/v) polyacrylamide gel 
and electroblotted onto a nitrocellulose membrane (Bio-Rad, UK). The membrane was blocked 
with 5% (w/v) non-fat dried milk and 0.1% (v/v) TWEEN® 20 in TBS, and then 
immunoprobed using each primary antibody at 4°C for 15 hours. To investigate protein 
phosphorylation the following antibodies detecting phosphotyrosine or phospho-
serine/threonine at specific sites were used: polyclonal anti-phosphotyrosine (BD Transduction 
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laboratories, 1:250); monoclonal Phospho-(Ser/Thr)AMPK Substrate (P-S/T2), monoclonal 
Phospho-AKT Substrate (RXRXXS/T) (110B7E), monoclonal Phospho-PKA Substrate 
(RRXS/T), monoclonal Phospho-(Ser/Thr)ATM/ATR Substrate (P-S3-101),  monoclonal 
Phospho-(Ser) PKC Substrate (P-S3-100), monoclonal Phospho-(Ser) CDKs Substrate (1:1000 
Cell Signalling Technology, UK) and polyclonal anti-GFP (1:2500 ab290, Abcam UK). In each 
blot, equal volumes of GFP-precipitates and “beads only”- precipitates were analysed for both 
treatments. Primary antibody binding was revealed with horseradish peroxidase (HRP)-
conjugated secondary antibody for 1 hour at room temperature. Immunoreactive bands were 
visualized by enhanced chemiluminescence using ECL detection kit (Geneflow, UK) and blots 
were imaged using LAS4000 imaging system (GE Healthcare, UK). Densitometric analysis 
was performed using AIDA (Advanced image Data Analyser) image analyser software. 
 
2.8 Extracellular TG2 activity assay 
Extracellular TG2 activity was measured through the enzyme’s ability of incorporating 
biotinylated cadaverine (BTC) (Molecular Probes, The Netherlands) into fibronectin (Sigma, 
UK) as previously described [42]. This assay was performed using 4×104 cells per well, and 
cells were incubated in the presence of BTC for 1 hour at 37° C. 
 
2.9 Extracellular TG2 and GFP immunofluorescent staining 
For immunofluorescent staining of extracellular TG2 or GFP, cells were plated in 8-well 
chamber slides and cultured overnight prior to staining. Cells were fixed with 3% 
paraformaldehyde (PFA) for 8 minutes at room temperature and blocked with 3% (w/v) BSA 
in PBS for 30 minutes at 37° C. Extracellular TG2 was detected by incubation with a 1:50 
dilution of mouse monoclonal anti-TG2 antibody IA12 [43] in blocking solution, overnight at 
4˚C, followed by a 1 hour incubation at room temperature with secondary goat anti-mouse 
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antibody Alexa Fluor® 598. Extracellular EGFP was detected by incubating with a 1:500 
dilution of rabbit polyclonal anti-GFP antibody in blocking solution, overnight at 4˚C, followed 
by a 1 hour incubation at room temperature with 1:500 dilution of Alexa Fluor® 568-
conjugated donkey anti-rabbit antibody in blocking solution. Slides were mounted with 
Vectashield® mounting medium containing DAPI. Images were obtained by acquiring 1 µm 
sections that were then merged to project the staining from the apical to the basal side of cells 
(20 μm specimens). 
 
2.10 Lactate dehydrogenase (LDH) bioassay 
LDH assay was performed using Pierce LDH Cytotoxicity Assay kit (Thermo Scientific, UK) 
following the manufacturer’s protocol.  
 
2.11 Statistical analysis and software 
Data is shown as mean + SEM. Data analyses were performed using unpaired T-test with 
Welch’s correction. A probability of 95% (p<0.05) was taken as significant. 
Putative phosphorylation sites of Homo sapiens TG2 protein sequence (EC:2.3.2.13) were 







3.1 TG2 export depends on cell surface Sdc4/HS in NRK-52E tubular epithelial 
cells  
Since extracellular TG2 was elevated in experimental and human diabetic nephropathy, 
glucose is believed to be one of the stimuli that can cause cellular release of TG2. To optimise 
the glucose concentrations that trigger TG2 translocation on the cell surface, a rat renal 
proximal epithelial-like tubular cell line (NRK-52E) [44] was treated with increasing 
concentrations of glucose for 96 hours, starting from 6 mM glucose, which may be 
representative of a normoglycemic environment, to 24 mM and 30 mM glucose concentrations, 
representative of extreme hyperglycemia. Increased cell surface TG2 activity was detected in 
cells cultured in glucose concentration above 18 mM (p<0.001) (Fig 1A). TG2 
immunofluorescence revealed a punctuate staining which was visibly enhanced by higher 
levels of glucose, suggesting that the increased cell surface TG2 activity resulted from elevated 
cellular release of TG2 (Fig 1B).  The punctate pattern was consistent with possible 
extracellular vesicles containing TG2, as we previously described [22]. 
To test the possibility that TG2 export depends on cell surface HS, cells were pre-treated with 
Hepase, which selectively cleaves HS chains, or Surfen, an antagonist of HS. Hepase or Surfen 
significantly abolished the increase in extracellular TG2 activity (Fig 1C). To test whether 
Sdc4 was the HS proteoglycan responsible for TG2 externalisation, its level was modulated by 
siRNA silencing. Knockdown of Sdc4 led to over 50% reduction of cell surface TG2 (Fig 1D-
E), comparable to that achieved by Hepase digestion and Surfen, suggesting that it is the main 




Fig 1: Glucose induces HS and syndecan-4 dependent externalisation of TG2. (A,B) NRK-52E 
cells were cultured in different concentrations of glucose for 96 hours. (A) The extracellular activity of 
TG was detected through the enzyme’s ability of incorporating BTC in FN by living cells. Data 
represent mean absorbance (Abs) (450 nM) ± SEM, n = 3 independent experiments undertaken in 
triplicates. Statistically significant changes are expressed relative to the values at 6 mM Glucose. (B) 
TG2 immunofluorescent staining was performed in cells growing in 6 mM glucose and 24 mM glucose 
(magnification 63X). (C) Cells growing in 24 mM glucose were treated with 30 mU/ml Hepase or 12 
M Surfen, which was followed by measurement of extracellular TG2 activity as described above. Data 
represent mean absorbance (450 nM) ± SEM, n = 3 independent experiments undertaken in triplicates. 
(D,E) NRK-52E cells were transfected with 100 nM Rat Sdc4 – targeting siRNA for 24 hours. The 
same cells transfected with 100 nM non-targeting scrambled siRNA were used as control. (D) 
Extracellular TG2 activity was measured as described above. Data represent mean absorbance (450 
nM), normalised for the control, ± SEM, n = 3 independent experiments undertaken in triplicates. (E) 
The relative expression of Sdc4 mRNA after siRNA transfection was analyzed via qRT-PCR, using the 
ΔΔCt method. Cyclophilin A was employed as housekeeping gene. Differences in mRNA expression 
are here shown as fold change from the control (2
-ΔΔCt
) ± SEM.  
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3.2 The heparin binding domain of TG2 is required for TG2 cell surface 
availability 
To test whether the interaction of HS with the heparin binding site of TG2 is responsible for its 
cell surface location, NRK-52E cells were transiently transfected with previously characterised 
TG2 heparin binding mutants [27], and the level of cell surface TG2 measured. Mutant cDNAs 
were selected based on enzymatic activity and thermal shift analysis described in our previous 
work [27], as they expressed mutant TG2s with similar enzymatic activity and stability to the 
WT enzyme; moreover, they could be modulated by Ca2+ and GTP like the wild type enzyme 
[27, 30]. Mutant M1c disrupted the 261-LRRWK-265 sequence while M3 the 598-KQKRK-
602 TG2 sequence of TG2. Both clusters are central for heparin binding as they form a 
composite heparin binding site when TG2 is in the closed conformation. Their mutation 
completely blocks heparin binding of TG2 when measured by surface plasmon resonance [27]. 
M1c and M3 were expressed as EGFP-tagged proteins by subcloning in pEGFP-N1 and 
transfection of the constructs into NRK-52E cells. Immunoblotting of total cell lysates revealed 
that the wild type and mutant forms of EGFP-tagged TG2 (100 kDa), were expressed at a 
comparable level and several times more than the endogenous TG2 (75 kDa) (Fig 2A). To 
verify whether the transfection of either WT (pEGFP-N1-TG2) or mutant TG2 (pEGFPN1-
TG2(M1c) and pEGFP-N1-TG2(M3) was also accompanied by cellular release of TG2, the 
level of externalised TG2 was detected by an anti-EGFP antibody in not permeabilised cells, 
and intensities values normalised per transfection efficiency (monitored via EGFP 
fluorescence) (Fig 2B). Cells transfected with WT TG2 displayed a marked punctate pattern of 
extracellular EGFP-TG2 (denoted by the red fluorescence), which was significantly reduced in 
cells transfected with TG2 heparin binding mutants, when the extracellular red staining was 
quantified by image analysis and normalised for either total EGFP-TG2 (green) or cell nucleus 
(blue). This quantification suggests that the TG2 heparin binding site plays a significant role in 
TG2 export. Heparan sulphate chains are characteristic of syndecan transmembrane receptors, 
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which are present at discrete locations on the cell surface but also in extracellular vesicles, and 
of extracellular matrix proteoglycans such as perlecan, all interacting partners of TG2 [22]. 
Mutation of the heparin binding site however did not completely abolish TG2 externalisation. 
This data was confirmed when availability of cell surface TG2 was measured enzymatically 
(Fig 2C): cells transfected with both TG2 heparin binding mutants (M1c and M3) displayed 
lower cell surface TG2 activity than cells transfected with wild type TG2 (WT), however higher 
than that of mock transfected cells, given the considerable overexpression of the exogenous 
TG2 forms. This data suggests that mutation of the heparin binding site is important for the 





Fig 2: The heparin binding site of TG2 is required for TG2 secretion. (A,B) NRK-52E cells cultured 
in 24 mM glucose for 96 hours were transiently transfected by electroporation with 5 µg of pEGFP-N1-
plasmid containing either TG2(WT), TG2(M1c) and TG2(M3). A mock transfection was performed as 
a control. (A) Post-transfection, the expression of wild type and mutant EGFP-TG2 was monitored by 
western blotting of total cell lysates using anti-TG2 antibody and anti-actin antibody to reveal the 
loading control actin; densitometric analysis of the transfected EGFP-TG2 (black arrowhead) and the 
endogenous TG2 (grey arrowhead) of a typical experiment is shown (values are normalised per loading 
control). (B) Extracellular EGFP-TG2 chimera was detected by immunofluorescent staining on fixed 
(2% PFA) but not permeabilised cells by a rabbit polyclonal anti-GFP antibody followed by a goat anti-
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rabbit Alexa 568 secondary antibody. Nuclei were stained with DAPI. Representative pictures at 100X 
magnification are here shown. Cell surface and matrix bound EGFP-TG2 was quantified by ImageJ 
intensity analysis (8 non overlapping images per section) and presented either as mean relative intensity 
of red over green (total EGFP-TG2) ± SEM, or red over blue (nuclei) ± SEM, and expressed relative to 
the TG2(WT) transfected cells (equalised to 1). (C) The cell surface activity of TG2 was detected 
through the enzyme’s ability of incorporating BTC in FN by living cells. Data represent mean 




3.3 Importance of membrane fusion for TG2 externalisation in NRK-52E 
cells 
NSF vesicle-fusing ATPase is required for intracellular SNARE (Soluble NSF Attachment 
protein Receptor)-mediated membrane fusion events, including exocytosis. Interestingly, 
together with other proteins with vesicular transport function, it was identified in the recently 
elucidated TG2 interactome, as specifically associated with TG2 membranes isolated from 
normal kidneys [22]. NEM, a specific inhibitor of NSF ATPase [45] was shown to interfere 
with TG2 secretion before [31]. Therefore, we evaluated consequences of NSF ATPase 
inhibition on TG2 release from NRK-52E at 24 mM glucose stimulation.  
NRK-52E WT cells showed a punctate pattern of extracellular TG2 antigen staining that was 
significantly reduced upon NEM treatment when the intensity of extracellular TG2 (red) over 
the nuclei (blue) was expressed relative to the control untreated cells (Fig 3A). Similarly, also 
EGFP-TG2 stably expressing clone [22] displayed a level of extracellular EGFP-TG2 (red) 
when quantified over the total EGFP-TG2 (green), although at a lower degree (Fig 3B). It is 
possible that TG2 overexpression slightly exceeds the endogenous trafficking systems in the 
transfected cells.  
Next, the implication of NSF ATPase on the availability of cell surface TG2 activity was 
explored. Cells displayed an increase in cell surface extracellular TG2 activity which was 
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dependent on cell adhesion time on fibronectin (Fig. 3C-D). At each time point, pre-incubation 
with NEM resulted in a significant reduction of cell surface TG2 in NRK-52E WT cells (Fig 
3C), and up to 4 hours post-seeding in the EGFP-TG2 transfected clone (Fig 3D). Unspecific 
release of cytosolic components by NEM in the employed conditions was ruled out by a LDH 
assay (Fig 3E). These data imply that membrane fusion events such as exocytosis drive the cell 






Fig 3:  Inhibition of NSF vesicle-fusing ATPase leads to a reduction in extracellular TG2. (A,B) 
NRK-52E WT TEC and EGFP-TG2 overexpressing NRK-52E, cultured in 24 mM glucose as described 
previously, were incubated with 0.6 μM (NEM) for 30 minutes. (A) Immunofluorescent staining of 
extracellular TG2 was performed in fixed (3% PFA) but not permeabilised NRK-52E WT cells using a 
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mouse monoclonal anti-TG2 antibody (IA12) followed by a secondary goat anti-mouse antibody Alexa 
Fluor® 598. Extracellular TG2 was quantified by ImageJ intensity analysis on at least 8 non-
overlapping fields per treatment and expressed as mean relative intensity of red over blue (nuclei), 
normalised to the control cells without NEM (equalised to 1) ± SEM. (B) Extracellular EGFP-TG2 
chimera was detected on fixed (3% PFA) but not permeabilised cells using a Rabbit, UK polyclonal 
anti-GFP antibody (Abcam, UK) followed by a donkey anti-rabbit Alexa Fluor® 568 antibody, with 
red fluorescence. Nuclei were stained with DAPI. Extracellular EGFP-TG2 (B) was quantified as 
described in A and expressed as mean relative intensity of red over green (total EGFP-TG2), normalised 
to the control cells without NEM (equalised to 1) ± SEM. Significance of the differences between 
treatments was determined by unpaired t-test: *= p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
Representative pictures at 200X magnification are shown. (C) WT or (D) EGFP-TG2 overexpressing 
NRK-52E TEC were pre-treated with 0.6 mM NEM for 30 minutes and seeded in a 96-well plate 
(20,000 cells/well) in quadruplicates and extracellular TG2 was detected as described in the Methods, 
for 2, 4 and 6 hours. Non-treated cells were used as a control. The values are average absorbances (450 
nm) of three independent experiments, each undertaken in quadruplicates, normalised for the relative 
control (equalised to 1) ± SD, N=3. (E) WT or EGFP-TG2 overexpressing NRK-52E TEC were 
incubated with different concentrations (0 to 1 μM) of N-ethylmaleimide (NEM) for 30 minutes. After 
incubation, cell viability was measured by Lactose Dehydrogenase bioassay. Data are expressed as 
spontaneous LDH Release (Abs 490 nm – Abs 680nm) at each concentration for each cell line ± SD. 
** represents significant difference (p<0.01) in LDH release between NRK52WT and EGFP-TG2 
transfected clone.  
 
3.4 Glucose induces TG2 phosphorylation in NRK-52E cells 
Data so far convincingly point at a Sdc4-dependent vesicular secretion of TG2 upon glucose 
stimulation, which is predominantly responsible for TG2 externalisation, however not all 
extracellular TG2 may be controlled by this pathway. As protein phosphorylation drives the 
HS-dependent translocation of FGF2 [35, 36], possible phosphorylation of TG2 upon glucose 
stimulation was explored. Firstly, putative phosphorylation sites of Homo sapiens TG2 protein 
(EC:2.3.2.13) were predicted using NetPhos (Supplementary Table 1). Among the residues 
with higher phosphorylation potential, tyrosine (Y) phosphorylation sites (Y-369, Y-583 and 
Y-503) had a high score, but tyrosine and threonine phosphorylation sites were lower in number 
comparing to serine residues in TG2. Then we explored TG2 phosphorylation in EGFP-tagged 
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TG2 immunoprecipitated from cell lysates via beads conjugated to anti-EGFP antibody. 
Specificity of immunoprecipitation was tested using “beads only” controls which showed no 
EGFP immunoreactivity (Supplementary Figure 1). 
In NRK-52E cells expressing EGFP-tagged TG2, glucose stimulation increased TG2 
externalisation (Fig 4A). To explore glucose-induced TG2 secretion and phosphorylation, cells 
were cultured in medium with high glucose (30 mM) and the phosphorylated EGFP-TG2 100 
kDa band, which was detected after precipitation, was visibly increased (Fig 4B-C). Glucose 
induced general tyrosine phosphorylation of TG2 (Fig 4B) and also serine/threonine 
phosphorylation (Fig 4C). In particular, glucose induced protein kinase A (PKA)-mediated 
phosphorylation and cyclin-dependent kinase (CDK) phosphorylation (Fig 4C). Interestingly, 
cyclin-G-associated kinase appeared to target TG2 also in cells cultured in low glucose, 
compared to the other serine/threonine kinases; moreover, CDK was identified as significantly 
associated with TG2 in the TG2-interactome of fibrotic kidneys in the murine urinary ureteric 
obstructions (UUO) model [22], corroborating this finding that TG2 is a CDK target. Instead, 
RAD3-related kinase (ATM/ATR), protein kinase C (PKC), protein kinase B (Akt), and 5' 
AMP-activated protein kinase (AMPK) did not appear to phosphorylate the enzyme as no 
convincing band was seen at 100 kDa (black arrowhead) when EGFP-precipitates were probed 
for these kinase’s -dependent phosphorylation (Fig 4C). Therefore, for the first time we have 
shown that glucose concentrations which trigger TG2-release into the extracellular 
environment from tubular epithelial cells also induce TG2 phosphorylation. Whether the two 





Fig 4: Glucose induced externalisation and phosphorylation of EGFP-TG2 
(A) EGFP-TG2 overexpressing NRK-52E clone was cultured in different concentrations of glucose for 
96 hours. Extracellular activity of TG was measured as described in Methods. Data represent mean 
absorbance (Abs) (450 nM) ± SEM, n = 3 independent experiments undertaken in triplicates. 
Statistically significant changes are expressed relative to the values at 6 mM Glucose. (B-C) NRK-52E 
EGFP-TG2 overexpressing clones were subjected to glucose stress to simulate a pro-fibrotic condition 
(5 mM glucose = - / 30 mM glucose = +) and EGFP-TG2 chimera was immunoprecipitated from equal 
amounts of cell lysate (750 μg) with a rabbit polyclonal anti-GFP antibody (Abcam, UK). Equal 
volumes (40 μl) of GFP-immunoprecipitated proteins (IP: GFP) were screened for the presence of 
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phosphorylated tyrosine, serine or threonine by Western blotting using specific antibodies as described 
in the Methods. Immunoreactive bands were detected by enhanced chemiluminescence (Geneflow, UK) 
after incubation with appropriate HRP-conjugated secondary antibody. The blot was then stripped and 
probed with rabbit polyclonal anti-GFP (Abcam, UK), followed by goat anti-rabbit IgG conjugated to 
HRP (Dako) to confirm the immunoprecipitation (WB: GFP). The EGFP-TG2 chimera expected MW 
is 100 kDa (arrowhead). The figure shows representative blots for each antibody employed. Asterisk 
represent co-eluted IgGs (** = Heavy Chain; * = Light Chain). Red circles identify phosphorylated 
EGFP-TG2. (B) Rabbit polyclonal anti-phosphotyrosine; (C) Rabbit monoclonal Phospho-PKA; Rabbit 
monoclonal Phospho-(Ser) CDKs; Rabbit monoclonal Phospho-(Ser/Thr) ATM/ATR; Rabbit 
monoclonal Phospho-(Ser) PKC; Rabbit monoclonal Phospho-AKT; Rabbit monoclonal Phospho-
(Ser/Thr) AMPK. Degree of phosphorylation of the 100 kDa TG2 band was quantified by densitometric 





4. Discussion  
 
Abnormal ECM accumulation causing expansion of glomerular and tubulointerstitial basement 
membranes, increased mesangial matrix and interstitial deposition is a common feature of CKD 
with different aetiology. TG2 plays a key role in this process by accelerating ECM deposition, 
stabilising ECM [18] and activating the fibrogenic cytokine TGF-β [19]. Regulation of 
extracellular TG2 is beneficial to CKD by slowing down the progression of the disease [25, 
26]. Therefore, it is important to understand how TG2 is externalised from renal cells, and 
targeting key factors involved in TG2 cell surface localisation and export may affect kidney 
fibrosis without the lethal side effects brought by the pan-TG inhibition. 
Recent progress using an in vivo proteomic approach has led to the identification of TG2 
interactome in kidney membranes, a powerful tool which in combination with primary and 
immortal tubular cell models has revealed that TG2 is externalised via extracellular vesicles. 
Among the TG2 partners, Sdc4 is one of the better characterised components of the TG2 
interactome. Firstly, there is a direct association of Sdc4 and TG2 [46]; secondly, when the 
kidney was subjected to subtotal nephrectomy or damage caused by aristolochic acid [47], 
increased extracellular TG2 was detected to be colocalised with HS chains [20, 43]; and finally, 
the protective effect of Sdc4 deletion on kidney fibrosis was evident in experimental CKD 
models by lowering levels of extracellular TG2 and TG2 activity [43]. It has been recently 
hypothesized that TG2 may be recruited as an HS binding cargo and targeted to small vesicles 
by Sdc4 [22].  
However, not all the 217 proteins directly or indirectly associated with TG2 in the UUO or 
sham kidney interactome were validated or understood [22]. In this study, glucose, a reliable 
stimulus among several renal stress factors (eg. hypoxia, acidosis, albumin overload and 
hemodynamic change etc) that up-regulates extracellular TG2 expression [40] was used to 
boost cell surface TG2 in NRK-52E TEC. Glucose concentrations simulating the clinical 
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hyperglycemic status induced TG2 externalisation, which was low and hardly detectable in the 
normoglycemic-like conditions. Here, we have shown for the first time that the heparin binding 
site of TG2 [27] is required for the availability of TG2 at the surface of NRK-52E TEC, and 
that HS/Sdc4 is needed for TG2 cell surface trafficking in TEC.  
Another less characterised partner of the TG2 kidney interactome [22] is NSF ATPase, a 
protein necessary for most intracellular vesicular trafficking and membrane fusion events [45, 
48-50] including exosome secretion by multivesicular body fusion [51]. Here we have 
validated the involvement of NSF ATPase in the externalisation of TG2 stimulated by glucose 
stress in NRK-52E TEC, showing that inhibition of NSF ATPase leads to a significant 
reduction in both TG2 cell surface antigen and activity. These data are consistent with a 
vesicular pathway of secretion for TG2. 
Based on the TG2 interactome, cyclin-G-associated kinase GAK is a specific partner of TG2 
in the UUO kidney at a point where TG2 is specifically released from TEC in the tubular 
interstitial space [22]. Here we show that TG2 is phosphorylated at serine/threonine consensus 
sequences which are target for cyclin-G-associated kinase GAK. TG2 phosphorylation has 
been previously reported at serine-216 by PKA [52], however to our knowledge 
phosphorylation and partnership with GAK is a novel finding. This finding is consistent with 
TG2 vesicular trafficking, given GAK’s relation with vesicle-mediated transport, particularly 
the uncoating of clathrin [53, 54]. 
Work by the group of Aeschlimann [55] has proposed an alternative TG2 secretion pathway 
by direct translocation, involving the pore-formation function of purinergic P2X7 receptor 
induced by extracellular ATP in the context of inflammation. Absence of P2X7 in the TG2 
interactome in kidney suggested that this pathway may not be shared [22], however we cannot 
exclude its involvement in this cell line under appropriate stimulus. 
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HS binding is a hallmark of TG2 secretion that has also been involved in the secretion of FGF-
2, moreover TG2 has affinity for phosphoinositides [31] and we now know it is phosphorylated 
upon secretory stimulus. Our previous work showed the need for an intact fibronectin (FN) N-
terminal binding site for TG2 secretion from TEC, which is crucial for a correct tertiary 
structure [56]. Although there are common factors in the export of TG2 and FGF2, further 
sophisticated investigations would be required to test whether these elements constitute a 
pathway and TG2 can also be secreted in a similar way by inducing lipidic membrane pores 
[38]. Diabetes mellitus is the main cause of end-stage kidney disease. Hyperglycemia 
significantly affects the renal tubules, with increase in proximal tubule reabsorption via Na+-
glucose cotransporters (consequent to increased glucose glomerular filtration), changes in cell 
proliferation and pathways which are linked to the fibrotic process [57]. Here we have shown 
that vesicular HS-dependent externalisation of TG2 and TG2 phosphorylation triggered by 
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